ABCF1 Expression Assay for Variable Psilocybin Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in microdosing psychedelics lies in accurately determining the varying concentrations of psychedelic compounds in natural products, which can vary significantly, necessitating a precise method to ensure effective dosing.
Innovation Solution
A method is developed based on ATP-binding cassette sub-family F member 1 (ABCF1) expression, involving determining ABCF1 expression in a subject, administering a microdose if expression is below a threshold, and repeating the process until the desired level is achieved, using reporter genes under the ABCF1 promoter to quantify psychedelic compounds like psilocybin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If natural products containing psychedelic compounds are used for microdosing, then the availability and ease of administration are improved, but the precision of dosing deteriorates due to varying concentrations of psychedelic compounds in different natural products
Solution Approach 1:
The patent employs ABCF1 expression levels as a biomarker feedback system to monitor and adjust psychedelic dosing. By measuring ABCF1 expression in subject samples and using this information to determine subsequent dosing amounts, the system achieves precise dose control despite using natural products with variable concentrations. The feedback loop enables dynamic adjustment of microdose amounts based on individual subject response and actual compound exposure.
2Adaptability or versatility
If varying concentrations of psychedelic compounds in natural products are used, then the versatility and natural source availability are improved, but the reliability of achieving therapeutic effect deteriorates due to inconsistent dosing
Solution Approach 1:
The patent uses ABCF1 expression monitoring to create a feedback-controlled dosing system that ensures reliable therapeutic outcomes. By measuring ABCF1 expression levels in subject samples and adjusting subsequent microdose administration based on these measurements, the system compensates for the variable concentrations in natural products. This feedback mechanism transforms an unreliable variable-input system into a reliable controlled-output system, ensuring consistent therapeutic effect achievement.
Solution Approach 2:
The patent changes the parameter used for dosing decisions from fixed natural product amounts to dynamic ABCF1 expression levels. Instead of administering fixed amounts of natural products with unknown variable concentrations, the system adjusts microdose amounts based on measured ABCF1 expression parameters, thereby ensuring reliable therapeutic effect regardless of natural product concentration variability.
3Ease of manufacture
If fixed dose protocols are used for psychedelic administration, then the simplicity and standardization are improved, but the precision of individualized dosing deteriorates due to inter-subject variability in response
Solution Approach 1:
The patent replaces fixed dose protocols with feedback-controlled individualized dosing using ABCF1 expression levels. By measuring ABCF1 expression in each subject's samples and using these measurements to determine personalized microdose amounts, the system achieves precise individualized dosing while maintaining procedural standardization through the consistent use of ABCF1 as the dosing decision parameter.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate determination of psychedelic compound doses, ensuring consistent and effective microdosing by modulating ABCF1 expression levels, thereby standardizing the administration of substances like psilocybin.
Implementation Method 1
contacting a cell which is capable of expressing ABCF1 or a reporter gene under the control of the ABCF1 promoter with the sample, comparing the expression of ABCF1 or reporter with a standard to determine the amount of psilocybin in the sample
Data Source
AI summary
The present invention provides a method of determining the amount of a psilocybin in a sample, the method comprising contacting a cell which expresses ABCF1 with the sample, comparing the expression of ABCF1 with a standard to determine the amount of psilocybinin in the sample. Also provided are methods of microdosing based on ABCF1 expression.